On August 26, the U.S. Food and Drug Administration (FDA) approved Revolution Medicines’ Rasonque for the treatment of metastatic pancreatic cancer. Reuters reports, UNN writes.
Details
The drug is taken once a day in tablet form. It will be prescribed to patients with metastatic pancreatic cancer who have already received prior treatment or cannot undergo combination chemotherapy.
Ukraine simplifies medicine storage rules due to Russian strikes on warehouses26.08.26, 20:47
Rasonque blocks several forms of the RAS protein, which promotes tumor growth. In a large clinical trial, the drug demonstrated a doubling of survival rates among patients with an advanced form of the disease.
The FDA reviewed the drug through an accelerated procedure that reduces the standard review period from 10–12 months to one or two months. Before final approval, the regulator also allowed seriously ill patients to receive Rasonque through an expanded-access program.
WHO updates its assessment of cannabis risks for the first time in ten years26.08.26, 12:34
Revolution Medicines set the price of the drug in the United States at $39,800 for a 30-day supply. The company also announced that it would provide financial assistance to patients.
Analysts at RBC Capital Markets forecast that U.S. sales of the drug could amount to $28 million in the third quarter and $148 million in the fourth. In the long term, annual global sales of Rasonque could reach $11.5 billion.